Cryo Cell International (CCEL) Q3 2024 earnings summary

Executive summary

• Revenue for the nine months ended August 31, 2024 increased 2% year-over-year to $23.96 million, with Q3 revenue up 2.5% to $8.07 million, driven by higher processing and storage fees.

• Net income for the nine months was $2.26 million, with Q3 net income up 54% year-over-year to $1.05 million ($0.13 per share).

• Gains on marketable securities were $1.06 million for the nine months and $522,000 in Q3, both significantly higher than prior periods.

• Celle Corp. spinoff and related investments are on hold due to ongoing arbitration with Duke University, with damages sought exceeding $100 million.

• Strategic alternatives, including a regular dividend, are being explored to maximize shareholder value, but no assurance of transaction completion.

Financial highlights

• Gross margin improved as cost of sales decreased 1% year-over-year to $6.31 million for the nine months.

• Selling, general and administrative expenses rose 7% to $12.51 million, reflecting higher personnel and professional fees.

• Interest expense declined to $1.12 million from $1.41 million, aided by capitalized interest on facility construction.

• Cash and cash equivalents at August 31, 2024 were $197,437, down from $406,067 at November 30, 2023.

• Marketable securities gains contributed significantly to net income growth.

Outlook and guidance

• The company anticipates sufficient liquidity for at least the next 12 months, but future capital needs depend on the outcome of the Duke arbitration and related business expansion.

• No further investments in Duke-related activities are planned until arbitration is resolved, except for a comparability study estimated at less than $350,000.

• Board is considering instituting a regular quarterly dividend, reflecting strong cash generation and reduced spending forecasts.

• Strategic review process remains ongoing, with no guarantee of outcome.